Connect to share and comment

Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH (Reuters) - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status. The Basel-based company in a statement on Monday said it plans to file for U.S. approval of Bexsero as early as the second quarter of this year.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Drugmaker Novartis files patent suit against Biocon over Galvus

ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

Novartis replaces top management in Japan after probe on clinical trials

TOKYO (Reuters) - Novartis AG replaced the top managers at its Japanese unit on Thursday after a third-party probe found employees had acted questionably in clinical trials on a leukaemia treatment. The probe's findings included possible destruction of evidence and the potential obtaining of patients' personal data by employees of the Japanese unit, Novartis Pharma K.K. said in a statement.

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. The company also said it was freezing funding for clinical trials in the country in the wake of the scandal, which David Epstein, head of the firm's pharmaceutical division, branded "unacceptable and a clear violation of our code of conduct". Epstein told a press briefing in Tokyo that the senior managers "resigned, they are out of the company".

Novartis replaces top Japan executives over drug trial scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, told a news briefing in Tokyo that the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". "I'd like to once again apologise for Novartis' involvement in this issue," Epstein told reporters.

Novartis' top Japan executives quit over cancer drug scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, said the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". "I'd like to once again apologise for Novartis' involvement in this issue," Epstein told a press briefing in Tokyo.

Novartis replaces top Japan executives over drug trial scandal

Swiss pharmaceutical giant Novartis said Thursday it was replacing the top executives at its Japanese unit over allegations the division hid serious potential side effects of leukaemia treatments from regulators. David Epstein, the head of the firm's pharmaceutical division, told a news briefing in Tokyo that the senior managers "resigned, they are out of the company", adding that "this kind of behaviour is unacceptable and a clear violation of our code of conduct". kh-oh-pb/dan

Novartis CEO reshapes drugmaker for 'brutal' new world

By Caroline Copley and Ben Hirschler BASEL, Switzerland (Reuters) - Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending. At least one of the three sub-scale units - animal health, vaccines and over-the-counter medicines - is not expected to make the cut, he told Reuters in the clearest indication yet of how the review is progressing.
Syndicate content